- Home
- ASMB vs CHRS Comparison
ASMB vs CHRS Comparison
Compare ASMB & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- CHRS
- Stock Information
- Founded
- ASMB 2005
- CHRS 2010
- Country
- ASMB United States
- CHRS United States
- Employees
- ASMB N/A
- CHRS N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASMB Health Care
- CHRS Health Care
- Exchange
- ASMB Nasdaq
- CHRS Nasdaq
- Market Cap
- ASMB 100.5M
- CHRS 100.9M
- IPO Year
- ASMB 2010
- CHRS 2014
- Fundamental
- Price
- ASMB $14.72
- CHRS $1.10
- Analyst Decision
- ASMB Buy
- CHRS Strong Buy
- Analyst Count
- ASMB 2
- CHRS 4
- Target Price
- ASMB $35.00
- CHRS $6.13
- AVG Volume (30 Days)
- ASMB 23.4K
- CHRS 3.3M
- Earning Date
- ASMB 11-07-2024
- CHRS 11-06-2024
- Dividend Yield
- ASMB N/A
- CHRS N/A
- EPS Growth
- ASMB N/A
- CHRS N/A
- EPS
- ASMB N/A
- CHRS N/A
- Revenue
- ASMB $28,326,000.00
- CHRS $304,340,000.00
- Revenue This Year
- ASMB $267.67
- CHRS $3.33
- Revenue Next Year
- ASMB $46.15
- CHRS $16.77
- P/E Ratio
- ASMB N/A
- CHRS N/A
- Revenue Growth
- ASMB N/A
- CHRS 44.19
- 52 Week Low
- ASMB $8.16
- CHRS $0.66
- 52 Week High
- ASMB $19.93
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- ASMB 35.66
- CHRS 69.14
- Support Level
- ASMB $15.92
- CHRS $0.70
- Resistance Level
- ASMB $17.48
- CHRS $0.89
- Average True Range (ATR)
- ASMB 1.07
- CHRS 0.11
- MACD
- ASMB -0.25
- CHRS 0.05
- Stochastic Oscillator
- ASMB 28.54
- CHRS 86.27
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.